K
Klaus Pantel
Researcher at University of Hamburg
Publications - 566
Citations - 36666
Klaus Pantel is an academic researcher from University of Hamburg. The author has contributed to research in topics: Circulating tumor cell & Cancer. The author has an hindex of 90, co-authored 486 publications receiving 29848 citations.
Papers
More filters
Journal ArticleDOI
Detection and oncological impact of circulating tumor cells in bladder cancer patients with presence of copy number variations of circulating cell free DNA.
Armin Soave,Heidi Schwarzenbach,Malte W. Vetterlein,Jessica Rührup,Oliver Engel,Roland Dahlem,Margit Fisch,Klaus Pantel,Sabine Riethdorf,Michael Rink +9 more
TL;DR: Investigation of detection and oncological impact of circulating tumor cells (CTC) in bladder cancer patients with presence of copy number variations (CNV) of circulating cell-free DNA (cfDNA) treated with radical cystectomy found MLPA was suitable for characterization of CNV.
Proceedings ArticleDOI
Abstract 4960: Molecular characterization of in-vivo isolated EpCAM-positive circulating tumor cells in high-risk prostate cancer patients
Athina Markou,Marifili Lazaridou,Panagiotis Paraskevopoulos,Shukun Chen,Thomas Kroneis,M. Swierczewska,Joanna Budna,Andra Kuske,Tobias M. Gorges,Maciej Zabel,Peter Sedlmayr,Catherine Alix-Panabières,Klaus Pantel,Evi Lianidou +13 more
TL;DR: In vivo isolation of CTC in conjunction with a downstream molecular analysis is minimally invasive, and in combination with high specific and sensitive RT-qPCR assays for CTC detection and molecular characterization seems very promising.
Journal ArticleDOI
Influence of preoperatively detected circulating tumor cells on the outcome of patients with urothelial carcinoma of the bladder treated with radical cystectomy.
Michael Rink,Armin Soave,Felix K.-H. Chun,Roland Dahlem,Sarah Minner,Luis A. Kluth,Sascha Ahyai,Hans Heinzer,Roman Heuer,Christian Eichelberg,Oliver Engel,Shahrokh F. Shariat,Klaus Pantel,Margit Fisch,Sabine Riethdorf +14 more
TL;DR: Although CTC can not predict pathological or nodal stage, they are associated with inferior disease outcome, and detection of even 1 CTC/7.5 mL blood in UCB patients prior to RC is an independent predictor for disease recurrence and cancer-related death.
Proceedings ArticleDOI
Abstract OT1-03-05: The DETECT V-Study – Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemo- or endocrine therapy in addition with CDK4/6 inhibition in patients with HER2-positive and hormone-receptor positive metastatic breast cancer
T Romashova,Arkadius Polasik,Twp Friedl,Brigitte Rack,M Tzschaschel,Peter A. Fasching,F-A Taran,Andreas D. Hartkopf,Andreas Schneeweiss,Volkmar Mueller,A Bahriye,Klaus Pantel,Franziska Meier-Stiegen,Pauline Wimberger,Wolfgang Janni,Tanja Fehm,J Huober +16 more
Journal ArticleDOI
Evaluation of prevalence, number, and temporal changes of circulating tumor cells as assessed after 2 and 5 years of follow-up in patients with early breast cancer in the SUCCESS A study.
E Bauer,Julia Neugebauer,Ulrich Andergassen,Bernadette Jaeger,Julia Kathrin Jueckstock,Peter A. Fasching,Lothar Haeberle,Thomas W. P. Friedl,Iris Schrader,Andreas Lorenz,Hans Tesch,Mahdi Rezai,Elisabeth Thurner-Herrmanns,Andreas Schneeweiss,Matthias W. Beckmann,Klaus Pantel,Wolfgang Janni,Brigitte Rack +17 more
TL;DR: Descriptive data on CTC status prospectively evaluated 2 and 5 years after primary diagnosis in the German SUCCESS A study is presented.